The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Results from Belimumab Safety Study

Results from Belimumab Safety Study

July 13, 2018 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

New research has examined the long-term safety of belimumab and potential organ damage in patients with systemic lupus erythematosus (SLE). This open-label, ongoing, extension study included patients (N=738) originally enrolled in the two phase 3 clinical trials, BLISS 52 and BLISS 76, that led to the U.S. Food and Drug Administration’s approval of belimumab. The extension study followed patients for up to nine years.1

You Might Also Like
  • European Commission Approves Subcutaneous Belimumab for SLE; FDA Safety Alert for Febuxostat
  • Subcutaneous Belimumab Improves Systemic Lupus Srythematosus Outcomes
  • Ixekizumab Promising for Non-Radiographic Axial SpA; Plus FDA Approves Belimumab for Pediatric Lupus
Explore This Issue
August 2018
Also By This Author
  • European Commission Approves Subcutaneous Belimumab for SLE; FDA Safety Alert for Febuxostat

During the study, patients received intravenous belimumab every four weeks, along with standard SLE therapy. Safety was assessed at each visit. The Systemic Lupus International Collaborating Clinics/ACR Damage Index (SDI) was used to assess safety every 48 weeks. The study continued until belimumab became commercially available in all of the participant’s countries and included an eight-week follow-up period.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The percentage of patients with no change in SDI score from baseline was 94.3% at Year 1, 92.2% at Year 2, 90% at Year 3, 87.9% at Year 4, 87.5% at Year 5, 87.6% at Year 6 and 86.9% at Year 7. At Year 8, 87.7% of patients had no change in SDI score from baseline. This finding indicates low organ damage accrual and a stable safety profile, with no new safety signals for the treatment.

Over time, the incidence of adverse events remained stable or decreased. The most common adverse events were headache (n=205, 28%), nasopharyngitis (n=155, 21%), diarrhea (n=143, 20%), arthralgia (n=136, 19%) and influenza (n=134, 18%). In 9.4% of patients (n=69), the adverse event led to therapy discontinuation or study withdrawal. Eleven deaths were reported, one of which was possibly related to belimumab treatment (cardiogenic shock). Additionally, three instances of suicide attempt/ideation (0.4%) were reported. Infections of special interest included opportunistic infections, tuberculosis, herpes zoster (recurrent and disseminated) and sepsis.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

Reference

  1. Van Vollenhoven RF, Navarra SV, Levy RA, et al. Organ damage progression and long-term safety of belimumab (BEL) in patients with systemic lupus erythematosus (SLE): An extension of pivotal phase 3 bliss studies (OP0252). Ann Rheum Dis. 2018 Jun;77:175–176.

Filed Under: DMARDs & Immunosuppressives, Drug Updates Tagged With: belimumab, organ damage, organ failure, SLE, systemic lupus erythematosus (SLE)Issue: August 2018

You Might Also Like:
  • European Commission Approves Subcutaneous Belimumab for SLE; FDA Safety Alert for Febuxostat
  • Subcutaneous Belimumab Improves Systemic Lupus Srythematosus Outcomes
  • Ixekizumab Promising for Non-Radiographic Axial SpA; Plus FDA Approves Belimumab for Pediatric Lupus
  • OA Knee Pain Treatment Enters Clinical Trials, Ixekizumab Receives FDA Approval & Belimumab Promising for SLE Patients

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.